Pharma Focus Asia

Polaris Group Submits BLA for ADI-PEG 20 to U.S. FDA for Malignant Pleural Mesothelioma

Friday, November 17, 2023

Polaris Group, listed as TWSE:6550, has announced the initiation of the rolling submission of its Biologic License Application (BLA) for ADI-PEG 20 to the U.S. Food and Drug Administration (FDA). This submission aims to seek approval for the systemic treatment of patients with malignant pleural mesothelioma featuring non-epithelioid histology, in combination with a platinum agent and pemetrexed.

The decision to pursue a rolling submission follows the positive outcomes of the phase 3 trial of ADI-PEG 20, meeting both primary and secondary objectives related to progression-free survival and overall survival. The rolling submission approach allows the company to submit completed modules of the BLA progressively, potentially expediting the regulatory review process and approval timeline.

The initial submission covers the nonclinical and clinical components of the BLA for ADI-PEG 20, with plans to finalize the remaining chemistry, manufacturing, and controls components in the coming months. Polaris Group aims to actively seek priority review status for the BLA upon the final submission, a designation that, if granted, could further accelerate the regulatory review process.

Polaris Group, emphasized the promising results from clinical trials, indicating the potential of ADI-PEG 20 to address the medical needs of patients with malignant pleural mesothelioma. The comprehensive development program is designed to furnish robust data supporting the FDA's review.

Polaris Group, expressed the company's dedication to addressing the urgent medical needs of patients with malignant pleural mesothelioma. The submission represents a significant step toward expanding treatment options for affected patients in the U.S. If approved, ADI-PEG 20 could contribute to addressing hard-to-treat cancers.

ADI-PEG 20 is a novel therapy showing promise in treating malignant pleural mesothelioma, a rare and aggressive cancer primarily caused by asbestos exposure. Polaris Group's development program is focused on demonstrating its safety and efficacy in addressing the challenging medical needs of patients facing this condition. Additionally, three Phase 3 clinical studies with ADI-PEG 20 in other hard-to-treat cancers are currently underway.

Malignant pleural mesothelioma is a highly aggressive cancer affecting the lining of the lungs, primarily caused by exposure to asbestos. It is associated with poor prognosis and limited treatment options.

 

Source: globenewswire.com

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference